

# **Strengthening Training for Academia in Regulatory Science (STARS) Project:** The road so far

Dr. Viktorija Starokozhko

**MEB Science Day 2022** February 17<sup>th</sup> 2022

under grant agreement No. 825881








## **Academic Drug Development**

- Contribution of academia in drug discovery & ۲ development is increasing
- Especially in the field of advanced therapies ۲
- No EU academic drug marketing authorization holder ٠ till now




Year


Academic

Large company

SME


× Total





Sponsor variations in clinical gene- and cell-based therapy development







#### designed by icon



## CSA-STARS: <u>Strengthening Training of Academia in Regulatory Sciences</u> & Supporting Regulatory Scientific Advice


- Consortium of 21 partners from 18 European countries represented via their NCA & EMA (plus 4 associated partners) and DLR-PT
- Funding by European Commission
- Project period: January 2019 June 2022








## Interactions with Stakeholders –Communication is Key!










## Mind the (Knowledge) Gap

### A lot of support activities already exist:

- National level: Scientific Advice, Innovation Offices
- EU level: EMA's early development and advice services (Innovation Task Force, PRIME scheme, Scientific Advice, etc.)
- EU Innovation Network




Kallio et al., manuscript in preparation




## **Challenges in academia**

- **Communication** with regulators: poor, high-bar, different "language"
- Poor awareness of regulatory guidance and support
- Lack of general regulatory knowledge
- Lack of **knowledge** on development & methodology in academia (e.g. Clinical Trial Application)
- **Time**: difficulties to ask the right questions at the right time
- **Complexity** of the regulatory process






## Working Programme, Project Outcomes and Impact









## **Comprehensive Inventory (CI)**

Comprehensive overview of support services for regulatory activities

Listing	<mark>y Expertise Are</mark>	a	•
Country 🝦	Provider Type	Expertise	Provider Details
Spain	National Competent Authority	ATMPs	<u>⊕</u> AEMPS
Belgium	Public Actor	ATMPs	<u> </u> <u> </u> <u> </u> Antwerp University Hospital
France	Public Actor	ATMPs	<u>⊕</u> AP-HP
Germany	Public Actor	ATMPs	
Austria	National Competent Authority	ATMPs	👲 BASG / AGES
France	Public Actor	ATMPs	🕹 CHU Amiens Picardie
Spain	Public Actor	ATMPs	🕹 CIBER
Switzerland	Public Actor	ATMPs	<u> </u>
Germany	Public Actor	ATMPs	<u> </u>
Europe	Public Actor	ATMPs	
Germany	Public Actor	ATMPs	
Czech Republic	Public Actor	ATMPs	. Czech Clinical Research Infrastructure Network
Europe	Public Actor	ATMPs	🕹 EATRIS


Country 🖕	Provider Type	Support 🔒 Activity	Provider Details
Portugal	Public Actor	Assistance in clinical trial application	👲 2CA-Braga
Spain	National Competent Authority	Assistance in clinical trial application	<u> </u>
Belgium	Public Actor	Assistance in clinical trial application	Antwerp University Hospital
France	Public Actor	Assistance in clinical trial application	<u>&amp;</u> AP-HP
Germany	Public Actor	Assistance in clinical trial application	
Austria	National Competent Authority	Assistance in clinical trial application	👲 BASG / AGES
Germany	National Competent Authority	Assistance in clinical trial application	<u> </u>
Ireland	Public Actor	Assistance in clinical trial application	A Cancer Trials Ireland
Germany	Public Actor	Assistance in clinical trial application	<u>⊕</u> Center for Clinical Trials Tuebingen
France	Public Actor	Assistance in	👲 CHU Amiens Picardie

Direct support for clinical researcher! Visit our website: https://www.csa-stars.eu/Inventory-1721.html



**Comprehensive Inventory** 







## **STARS White Paper & 1st Stakeholder Workshop** Communication & Interaction Framework and its Gaps



Drug Discovery Today Volume 26, Issue 2, February 2021, Pages 283-288




Feature


Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational

#### gap

Viktoriia Starokozhko<sup>1, 2</sup>, Marko Kallio<sup>3</sup>, Åsa Kumlin Howell<sup>4</sup>, Anna Mäkinen Salmi<sup>4</sup>, Gunilla Andrew-Nielsen<sup>4</sup>, M. Goldammer<sup>5</sup>, Manja Burggraf<sup>6</sup>, Wiebke Löbker<sup>7</sup>, Anne Böhmer<sup>7</sup>, Eleonora Agricola<sup>8</sup>, Corinne S. de Vries<sup>9</sup>, Anna M.G. Pasmooij<sup>1</sup>, Peter G.M. Mol<sup>1, 2</sup>,  $\cong$ , on behalf of the STARS consortium







Aim:


Continuous regulatory training

Exchange with the research

Starokozhko et al, Drug Discovery Today, 2021


NCAs: national competent authorities; EMA: European Medicines Agence







## **STARS Pilots**





## **Pilot I** Transfer of an identified best practice example




- Poor awareness of regulatory support tools
- Difficulty in reaching sufficient level of regulatory knowledge (with attention to CTA)

#### **Topics of the online course:**

- Regulatory system and framework
- Essential regulatory knowledge in drug development
- Specific Regulatory Knowledge for Advanced Therapy Medicinal Products (ATMPs)







## **Pilot II** Initiation of a Novel Support Activity

STARS Survey data:

- Tool/s to improve the communication between regulators and academia
- Timely response is probably the most remarkable need

#### Concept: **one-stop-shop platform** for Spanish academia (September 2021)










#### Pilot Project II

Initiation of a novel support activity for improving success on regulatory Scientific Advice.











## **STARS Curricula**










## The STARS Common Strategy & 2<sup>d</sup> Stakeholder Workshop



#### What is the Common Strategy?

Strategic document with recommendations to improve the regulatory knowledge, awareness and skills of academia

#### What does it include?


Recommendations based on survey data, evaluation of pilots, input from stakeholders

#### To whom adressed?

European Commission, stakeholder in Europe and member states, e.g. ministries, policy maker, funders, academia, NCAs and public



## **Drug Development - From Lab to Patient**



designed by icon



### Acknowledgement





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825881

# https://www.csa-stars.eu/index.html